Hsd17b13 inipharm
WebINI 822, a small molecule inhibitor of 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13), being developed by Inipharm, for the treatment of severe liver INI ... 25 … WebInipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Stage: A. Total Funds Raised: $35.0M. Last Round Amount: …
Hsd17b13 inipharm
Did you know?
Web12 mrt. 2024 · Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. WebImmunohistochemical analysis of human tonsil tissue labeling HSD17B13 with ab122036 at 1/200 dilution. As expected, no positivity in lymphoid cells is shown. …
WebExtensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein. Web5 okt. 2024 · Inipharm, a biopharmaceutical company focused on discovering and developing therapies for liver and related diseases, today announced that it will be presenting data on the anti-fibrotic effects of...
WebNonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, in which prognosis is determined by liver fibrosis. A common variant in hydroxysteroid 17-beta … Web17-β hydroxysteroid dehydrogenase 13 (HSD17B13) belongs to a 15-member family that is involved in various metabolic processes, including steroid hormones, fatty acids, cholesterol, and bile acids ().The human HSD17B13 gene is located on chromosome 4 (4q22.1), and its expression is highly restricted to the liver, specifically in hepatocytes but not other cell …
Web8 jun. 2024 · Inipharm will also be presenting preclinical data on one of its small molecule HSD17B13 inhibitors at the International Liver Congress™ 2024, occurring in London. BELLEVUE, Wash. & SAN DIEGO, June 08, 2024--Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today …
WebThe company's research is focused on small molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases, … horror shortWeb2 nov. 2024 · 17β-hydroxysteroid dehydrogenase-13 is a hepatocyte-specific, lipid droplet-associated protein. A common loss-of-function variant of HSD17B13 (rs72613567: TA) protects patients against non ... lower slide lake campgroundWeb6 dec. 2024 · Asher Mullard. Industry investment into siRNA drugs is flowing again, with deals from Novo Nordisk and GlaxoSmithKline showcasing interest in RNAi-inducing oligonucleotides that knockdown levels ... lower sleeve tattoo ideasWebInipharm is a Frazier-founded company focused on discovering and developing therapies for severe liver diseases. The company is advancing a pipeline of small-molecule … lower sleeve tattoos for menWeb11 nov. 2024 · “HSD17B13 is a fascinating target with strong genetic links to numerous liver diseases. The Inipharm team, along with CRO partner Jubilant Biosys, has made excellent early progress in modulating this target with small molecules, and we are thrilled to support the company to accelerate their efforts towards the clinic,” said founding board member … horror short film hindiWebInipharm to Present Data on Anti-Fibrotic Effects of Its Development Candidate Targeting HSD17B13 at AASLD’s The Liver Meeting. Jun 8, 2024. Inipharm Appoints Chuhan … lower slimline expanderWebInipharm Appoints Chuhan Chung, M.D, as Chief Medical Officer to Advance HSD17B13 Program into the Clinic Liked by Rathnam … horror short film other side of the box alter